Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1098 | 1041 | 987 | 1253 | 1442 | 2107 |
Fund Return | 9.84% | 4.12% | -1.34% | 7.8% | 7.6% | 7.74% |
Place in category | 273 | 250 | 60 | 345 | 93 | 41 |
% in Category | 45 | 39 | 12 | 65 | 22 | 16 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS CH Institutional Fund 2 EquiP2X | 9.03B | 34.35 | 9.07 | 12.32 | ||
UBS CH Institutional Fund 2 EquiPAX | 4.49B | 28.57 | 7.61 | 9.70 | ||
UBS CH Vitainvest 50 World U | 4.39B | 8.31 | -0.67 | 2.51 | ||
UBS CH Institutional Fund 2 EquiSCX | 2.82B | 11.50 | -1.36 | 6.69 | ||
UBS CH Institutional Fund 2 EquiSCB | 2.82B | 11.45 | -1.42 | 6.63 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.49B | 9.01 | 1.94 | 5.88 | ||
Raiffeisen Futura Swiss Stock A | 2.14B | 7.81 | -1.29 | 5.90 | ||
UBS CH Equity Fund Swiss Income CHQ | 2.16B | 10.36 | 3.55 | 6.38 | ||
UBS CH Equity Fund Swiss Income CHF | 2.16B | 9.72 | 2.91 | 5.73 | ||
CH0502155648 | 2.16B | 10.53 | 3.73 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nestle | CH0038863350 | 19.19 | 74.94 | +1.24% | |
Novartis | CH0012005267 | 12.84 | 90.39 | +1.61% | |
Roche Holding Participation | CH0012032048 | 12.72 | 264.40 | +2.68% | |
UBS Group | CH0244767585 | 7.03 | 29.44 | +0.79% | |
Zurich Insurance Group | CH0011075394 | 6.01 | 551.80 | +0.69% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review